STOCK TITAN

Windward Bio IPO: OrbiMed fund buys 1.18M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Windward Bio Group AG (WWB) reported an IPO purchase and related preferred-share conversions and warrant exercise involving OrbiMed Private Investments IX, LP (OPI IX). On November 16, 2026, David P. Bonita, a director and 10% owner, reported transactions involving securities held of record by OPI IX. OPI IX purchased 1,176,471 common shares at $17.00 per share in the initial public offering. Its 3,561,936 Series A and 1,611,008 Series B Preferred Shares converted one-for-one into common shares immediately before the IPO closing, and it exercised warrants for 216,668 common shares at $0.02 per share. The report also lists 232 shares delivered or withheld for payment of exercise price or tax liability; a footnote says they were withheld in connection with the warrant exercise. It lists a direct stock option covering 22,675 common shares for Bonita, with a $17.00 exercise price and vesting in 12 equal monthly installments beginning December 31, 2026, subject to continuous service. Bonita disclaimed beneficial ownership except to the extent of any pecuniary interest.

Insider Bonita David P
Role Director, 10% Owner
Bought 1,176,471 shs ($20.00M)
Increase in Position 221.3%
Type Security Shares Price Value
Conversion Series A Preferred Shares F4, F2, F3 3,561,936 $0.00 $0.00
Conversion Series B Preferred Shares F4, F2, F3 1,611,008 $0.00 $0.00
Exercise Warrants (right to buy) F5, F7, F2, F3 216,668 $0.00 $0.00
Purchase Common Shares F1, F2, F3 1,176,471 $17.00 $20.00M
Conversion Common Shares F4, F2, F3 3,561,936 -- --
Conversion Common Shares F4, F2, F3 1,611,008 -- --
Exercise Common Shares F5, F2, F3 216,668 $0.02 $4K
Exercise Price or Tax Liability Common Shares F6, F2, F3 232 $17.00 $4K
Holding Stock Option (right to buy) F8 -- -- --
Holdings After Transaction: Series A Preferred Shares — 0 shares (Indirect, See footnotes); Series B Preferred Shares — 0 shares (Indirect, See footnotes); Warrants (right to buy) — 0 warrants (Indirect, See footnotes); Common Shares — 7,097,483 shares (Indirect, See footnotes); Stock Option (right to buy) — 22,675 options (Direct)
Holdings Before and After: Series A Preferred Shares, 3,561,936 to 0 shares (Indirect, See footnotes); Series B Preferred Shares, 1,611,008 to 0 shares (Indirect, See footnotes); Warrants (right to buy), 216,668 to 0 warrants (Indirect, See footnotes); Common Shares, 531,632 to 7,097,483 shares (Indirect, See footnotes)
Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (8)
  1. F1. Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering.
  2. F2. These securities are held of record by OrbiMed Private Investments IX, LP. ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. The Reporting Person is a member of OrbiMed Advisors.
  3. F3. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
  4. F4. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
  5. F5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
  6. F6. Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants.
  7. F7. The warrants are fully vested and exercisable.
  8. F8. These options will vest in 12 equal monthly installments on the last day of the relevant month commencing on December 31, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
Common shares purchased 1,176,471 shares OPI IX purchase in the initial public offering on November 16, 2026
Purchase price $17.00 per share OPI IX common-share purchase on November 16, 2026
Series A Preferred Shares converted 3,561,936 shares Converted one-for-one into common shares immediately before the IPO closing on November 16, 2026
Series B Preferred Shares converted 1,611,008 shares Converted one-for-one into common shares immediately before the IPO closing on November 16, 2026
Common shares from warrant exercise 216,668 shares Warrant exercise on November 16, 2026
Warrant exercise price $0.02 per share Exercise price stated in U.S. dollars for the November 16, 2026 exercise
Shares delivered or withheld 232 shares Reported in connection with warrant exercise on November 16, 2026
Common shares underlying direct stock option 22,675 shares Direct option holding listed on November 16, 2026
initial public offering financial
"purchased in the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
voting and investment power regulatory
"may be deemed to have voting and investment power"
beneficial ownership regulatory
"disclaims beneficial ownership of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
fully vested and exercisable technical
"warrants are fully vested and exercisable"
continuous service technical
"subject to the Reporting Person's continuous service"
1-to-1 basis technical
"converted into the number of Common Shares on a 1-to-1 basis"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many WWB common shares did OrbiMed Private Investments IX purchase?

OrbiMed Private Investments IX, LP purchased 1,176,471 common shares at $17.00 per share in Windward Bio Group AG's initial public offering on November 16, 2026. No Rule 10b5-1 plan is reported.

What happened to WWB's Series A and Series B preferred shares?

OPI IX's 3,561,936 Series A and 1,611,008 Series B Preferred Shares converted one-for-one into common shares immediately before the closing of the initial public offering on November 16, 2026.

What were the terms of OPI IX's WWB warrant exercise?

OPI IX exercised warrants for 216,668 common shares at $0.02 per share. The exercise price is in U.S. dollars and reflects conversion from CHF at $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the issuer's board. The warrants were fully vested and exercisable and had a May 12, 2036 expiration date.

What is the vesting schedule for David P. Bonita's WWB stock options?

The direct stock option covering 22,675 common shares vests in 12 equal monthly installments on the last day of each month beginning December 31, 2026, subject to Bonita's continuous service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bonita David P

(Last)(First)(Middle)
C/O WINDWARD BIO GROUP AG
AESCHENPLATZ 6

(Street)
BASEL4052

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
WINDWARD BIO GROUP AG [ WWB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares11/16/2026P1,176,471(1)A$171,708,103ISee footnotes(2)(3)
Common Shares11/16/2026C3,561,936A(4)5,270,039ISee footnotes(2)(3)
Common Shares11/16/2026C1,611,008A(4)6,881,047ISee footnotes(2)(3)
Common Shares11/16/2026M216,668A$0.02(5)7,097,715ISee footnotes(2)(3)
Common Shares11/16/2026F(6)232D$177,097,483ISee footnotes(2)(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Preferred Shares(4)11/16/2026C3,561,936 (4) (4)Common Shares3,561,936$00ISee footnotes(2)(3)
Series B Preferred Shares(4)11/16/2026C1,611,008 (4) (4)Common Shares1,611,008$00ISee footnotes(2)(3)
Warrants (right to buy)$0.02(5)11/16/2026M216,668 (7)05/12/2036Common Shares216,668$00ISee footnotes(2)(3)
Stock Option (right to buy)$17 (8)11/11/2036Common Shares22,67522,675D
Explanation of Responses:
1. Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering.
2. These securities are held of record by OrbiMed Private Investments IX, LP. ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. The Reporting Person is a member of OrbiMed Advisors.
3. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
4. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
6. Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants.
7. The warrants are fully vested and exercisable.
8. These options will vest in 12 equal monthly installments on the last day of the relevant month commencing on December 31, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
/s/ David P. Bonita11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading